← Leaderboards
Paul B Fisher
Virginia Commonwealth University
$21,846,479
Attributed
$25,419,558
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,870,133 · 19
By mechanism
R01$17,966,350 · 10
P01$11,157,036 · 5
K12$2,024,132 · 1
R21$647,865 · 2
R03$74,750 · 1
Top collaborators
- Devanand Sarkar9 shared
- Xiang-Yang Wang5 shared
- Swadesh K Das2 shared
- Joseph William Landry2 shared
- Joyce A Lloyd1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Devanand Sarkar$13,330,601
- Joseph William Landry$2,951,878
- Swadesh K Das$413,809
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesMalignant NeoplasmsPropertyMediatingApoptosisOncogenesMelanomaAnimal ModelProteinsMolecularNeoplasm MetastasisInsightNeoplastic CellGrowthTumorMouse ModelBaseSubtraction HybridizationCancer CellIn VitroCombinatorialGene ExpressionAngiogenesisInnovation
Grant awards (91)
Modulating growth, progression and metastasis in breast cancer by inhibiting MDA-9$619,098
R01 · FY2025 · CA · contact PI
Designer Cytokine Therapy of Hepatocellular Carcinoma$582,256
P01 · FY2025 · CA · contact PI
Interplay between tumor and microenvironment in bone metastasis$470,956
R01 · FY2025 · CA · contact PI
Modulating growth, progression and metastasis in breast cancer by inhibiting MDA-9$622,329
R01 · FY2024 · CA · contact PI
Designer Cytokine Therapy of Hepatocellular Carcinoma$596,066
P01 · FY2024 · CA · contact PI
Interplay between tumor and microenvironment in bone metastasis$447,407
R01 · FY2024 · CA · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$392,721
R01 · FY2024 · CA
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$61,505
R01 · FY2024 · CA
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$494,436
R01 · FY2023 · CA
Interplay between tumor and microenvironment in bone metastasis$461,537
R01 · FY2023 · CA · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$128,086
R01 · FY2023 · CA
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$66,972
R01 · FY2023 · CA
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$494,436
R01 · FY2022 · CA
Interplay between tumor and microenvironment in bone metastasis$461,537
R01 · FY2022 · CA · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$52,578
R01 · FY2022 · CA
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$504,528
R01 · FY2021 · CA
Interplay between tumor and microenvironment in bone metastasis$470,956
R01 · FY2021 · CA · contact PI
Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma$518,339
R01 · FY2020 · CA
Virginia Commonwealth University IRACDA$464,928
K12 · FY2016 · GM · contact PI
New transgenic animal model to study pancreatic cancer$178,234
R21 · FY2016 · CA · contact PI
New transgenic animal model to study pancreatic cancer$213,881
R21 · FY2015 · CA · contact PI
Virginia Commonwealth University IRADCA$10,463
K12 · FY2014 · GM · contact PI
Virginia Commonwealth University IRADCA$487,720
K12 · FY2013 · GM · contact PI
AEG-1: Novel Gene Involved in Malignant Glioma$282,853
R01 · FY2013 · CA · contact PI
Virginia Commonwealth University IRADCA$487,720
K12 · FY2012 · GM · contact PI
Pancreatic Cancer Management by Novel Gene Therapy & Dietary Agents$300,907
R01 · FY2012 · CA · contact PI
AEG-1: Novel Gene Involved in Malignant Glioma$300,907
R01 · FY2012 · CA · contact PI
MDA-7: Novel Cancer Therapeutic Gene$259,625
R01 · FY2012 · CA · contact PI
Screening strategy for small molecules inhibitors of cancer$37,375
R03 · FY2012 · MH · contact PI
Virginia Commonwealth University IRADCA$355,123
K12 · FY2011 · GM · contact PI
Pancreatic Cancer Management by Novel Gene Therapy & Dietary Agents$300,907
R01 · FY2011 · CA · contact PI
AEG-1: Novel Gene Involved in Malignant Glioma$300,907
R01 · FY2011 · CA · contact PI
MDA-7: Novel Cancer Therapeutic Gene$259,625
R01 · FY2011 · CA · contact PI
Screening strategy for small molecules inhibitors of cancer$37,375
R03 · FY2011 · MH · contact PI
AEG-1: Novel Gene Involved in Malignant Glioma$310,213
R01 · FY2010 · CA · contact PI
Pancreatic Cancer Management by Novel Gene Therapy & Dietary Agents$310,213
R01 · FY2010 · CA · contact PI
MDA-7: Novel Cancer Therapeutic Gene$267,654
R01 · FY2010 · CA · contact PI
Virginia Commonwealth University IRADCA$218,178
K12 · FY2010 · GM · contact PI
Translational Applications of mda-7/IL-24 in Cancer$1,353,467
P01 · FY2009 · CA · contact PI
MDA-7/IL-24: Therapy of Prostate Cancer$490,383
P01 · FY2009 · CA · contact PI
AEG-1: Novel Gene Involved in Malignant Glioma$310,213
R01 · FY2009 · CA · contact PI
Pancreatic Cancer Management by Novel Gene Therapy & Dietary Agents$310,126
R01 · FY2009 · CA · contact PI
MDA-7: Novel Cancer Therapeutic Gene$267,579
R01 · FY2009 · CA · contact PI
Translational Applications of mda-7/IL-24 in Cancer$1,329,682
P01 · FY2008 · CA · contact PI
MDA-7/IL-24: Therapy of Prostate Cancer$482,536
P01 · FY2008 · CA · contact PI
MDA-7: Novel Cancer Therapeutic Gene$266,759
R01 · FY2008 · CA · contact PI
Translational Applications of mda-7/IL-24 in Cancer$1,235,688
P01 · FY2007 · CA · contact PI
MDA-7/IL-24: Therapy of Prostate Cancer$362,273
P01 · FY2007 · CA · contact PI
Novel Approaches for Pancreatic Cancer Therapy$268,720
R01 · FY2007 · CA · contact PI
Role of EAAT2 and AEG-1 in Astrocyte Dysfunction and Neurodegeneration$221,620
P01 · FY2007 · NS · contact PI
Analysis of Progression of the Transformed Phenotype$180,847
R01 · FY2007 · CA · contact PI
Mda-5: Novel Apoptosis Inducing Gene$150,116
R01 · FY2007 · GM · contact PI
Analysis of Progression of the Transformed Phenotype$137,104
R01 · FY2007 · CA · contact PI
Mda-5: Novel Apoptosis Inducing Gene$122,439
R01 · FY2007 · GM · contact PI
Novel Approaches for Pancreatic Cancer Therapy$75,540
R01 · FY2007 · CA · contact PI
Translational Applications of mda-7/IL-24 in Cancer$1,239,416
P01 · FY2006 · CA · contact PI
Novel Approaches for Pancreatic Cancer Therapy$355,239
R01 · FY2006 · CA · contact PI
Analysis of Progression of the Transformed Phenotype$346,902
R01 · FY2006 · CA · contact PI
Mda-5: Novel Apoptosis Inducing Gene$290,851
R01 · FY2006 · GM · contact PI
Mda-7: Novel Cancer Therapeutic Gene$284,191
R01 · FY2006 · CA · contact PI
MDA-7/IL-24: Therapy of Prostate Cancer$279,685
P01 · FY2006 · CA · contact PI
Role of EAAT2 and AEG-1 in Astrocyte Dysfunction and Neurodegeneration$225,083
P01 · FY2006 · NS · contact PI
Translational Applications of mda-7/IL-24 in Cancer$1,292,322
P01 · FY2005 · CA
Novel Approaches for Pancreatic Cancer Therapy$363,788
R01 · FY2005 · CA
Analysis of Progression of the Transformed Phenotype$350,585
R01 · FY2005 · CA
Mda-5: Novel Apoptosis Inducing Gene$297,850
R01 · FY2005 · GM
Mda-7: Novel Cancer Therapeutic Gene$291,030
R01 · FY2005 · CA
MDA-7/IL-24: Therapy of Prostate Cancer$272,456
P01 · FY2005 · CA
Role of EAAT2 and AEG-1 in Astrocyte Dysfunction and Neurodegeneration$218,565
P01 · FY2005 · NS
Novel Approaches for Pancreatic Cancer Therapy$363,788
R01 · FY2004 · CA
Analysis of Progression of the Transformed Phenotype$301,135
R01 · FY2004 · CA
Mda-5: Novel Apoptosis Inducing Gene$297,850
R01 · FY2004 · GM
Mda-7: Novel Cancer Therapeutic Gene$291,030
R01 · FY2004 · CA
Role of EAAT2 and AEG-1 in Astrocyte Dysfunction and Neurodegeneration$212,497
P01 · FY2004 · NS
Novel Approaches for Pancreatic Cancer Therapy$363,788
R01 · FY2003 · CA
Mda-7: Novel Cancer Therapeutic Gene$291,030
R01 · FY2003 · CA
Analysis of Progression of the Transformed Phenotype$286,125
R01 · FY2003 · CA
Role of EAAT2 and AEG-1 in Astrocyte Dysfunction and Neurodegeneration$214,874
P01 · FY2003 · NS
NOVEL PROSTATE CANCER GENE AND MONOCLONAL ANTIBODY$467,166
R01 · FY2002 · CA
Mda-7: Novel Cancer Therapeutic Gene$291,030
R01 · FY2002 · CA
TARGETING THERAPY OF HUMAN BREAST CANCER$127,875
R21 · FY2002 · CA
ALTERED GENE PRODUCTS IN HIV-1 INFECTED ASTROCYTES$0
P01 · FY2002 · NS
NOVEL PROSTATE CANCER GENE AND MONOCLONAL ANTIBODY$455,332
R01 · FY2001 · CA
ALTERED GENE PRODUCTS IN HIV-1 INFECTED ASTROCYTES$173,158
P01 · FY2001 · NS
TARGETING THERAPY OF HUMAN BREAST CANCER$127,875
R21 · FY2001 · CA
PROGRESSION OF THE TRANSFORMED PHENOTYPE$48,965
R01 · FY2001 · CA
ALTERED GENE PRODUCTS IN HIV-1 INFECTED ASTROCYTES$0
P01 · FY2001 · NS
NOVEL PROSTATE CANCER GENE AND MONOCLONAL ANTIBODY$443,844
R01 · FY2000 · CA
PROGRESSION OF THE TRANSFORMED PHENOTYPE$234,156
R01 · FY2000 · CA
ALTERED GENE PRODUCTS IN HIV-1 INFECTED ASTROCYTES$201,851
P01 · FY2000 · NS
ALTERED GENE PRODUCTS IN HIV-1 INFECTED ASTROCYTES$173,158
P01 · FY2000 · NS